TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04991831: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Diseas

Sponsor: InSightec · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,474,400

Rescue Site Savings

+$970,000

Unlock Full NCT04991831 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04991831 Rescue Dossier →